Mark Sopwith

1.5k total citations
13 papers, 1.2k citations indexed

About

Mark Sopwith is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Molecular Biology. According to data from OpenAlex, Mark Sopwith has authored 13 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Radiology, Nuclear Medicine and Imaging, 4 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in Mark Sopwith's work include Monoclonal and Polyclonal Antibodies Research (5 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Adipose Tissue and Metabolism (2 papers). Mark Sopwith is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (5 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Adipose Tissue and Metabolism (2 papers). Mark Sopwith collaborates with scholars based in United Kingdom, Netherlands and United States. Mark Sopwith's co-authors include Roy Taylor, Francis Ofei, Steve Hurel, Alastair Forbes, Patricia K. Heath, G. K. T. Holmes, CJ Hawkey, J Freeman, Rose G. Long and Sue Stephens and has published in prestigious journals such as The Lancet, Diabetes and Hypertension.

In The Last Decade

Mark Sopwith

12 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Sopwith United Kingdom 9 528 339 279 273 250 13 1.2k
Alaa Afify United States 22 250 0.5× 205 0.6× 152 0.5× 98 0.4× 394 1.6× 57 1.5k
Nathalie Bâ France 9 599 1.1× 366 1.1× 217 0.8× 623 2.3× 495 2.0× 12 1.8k
Noriyoshi Ogawa Japan 23 236 0.4× 532 1.6× 192 0.7× 694 2.5× 307 1.2× 81 1.6k
J. Herbert United Kingdom 6 245 0.5× 483 1.4× 52 0.2× 134 0.5× 280 1.1× 10 1.0k
Isaac T. W. Harley United States 13 198 0.4× 424 1.3× 153 0.5× 154 0.6× 244 1.0× 22 943
Makoto Sueishi Japan 18 190 0.4× 293 0.9× 65 0.2× 216 0.8× 223 0.9× 50 1.0k
Toshihiko Hidaka Japan 21 145 0.3× 439 1.3× 96 0.3× 112 0.4× 181 0.7× 79 1.4k
S Fukuhara Japan 19 130 0.2× 408 1.2× 73 0.3× 97 0.4× 358 1.4× 40 1.3k
Nicholas K. Brown United States 13 175 0.3× 634 1.9× 71 0.3× 141 0.5× 266 1.1× 30 1.3k
Irena Kirman United States 20 169 0.3× 557 1.6× 284 1.0× 53 0.2× 235 0.9× 50 1.3k

Countries citing papers authored by Mark Sopwith

Since Specialization
Citations

This map shows the geographic impact of Mark Sopwith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Sopwith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Sopwith more than expected).

Fields of papers citing papers by Mark Sopwith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Sopwith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Sopwith. The network helps show where Mark Sopwith may publish in the future.

Co-authorship network of co-authors of Mark Sopwith

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Sopwith. A scholar is included among the top collaborators of Mark Sopwith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Sopwith. Mark Sopwith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Ofei, Francis, et al.. (2009). O-48: TNFα and insulin sensitivity in humans: effects in vivo of antibody blockade in obese NIDDM patients and in vitro upon human cultured myotubes. Experimental and Clinical Endocrinology & Diabetes. 104(S 02). 59–60.
2.
Bhushan, M., T.O. Bleiker, Michael H. Allen, et al.. (2002). Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. British Journal of Dermatology. 146(5). 824–831. 93 indexed citations
3.
4.
Perkins, Alan C., Jan C. Roos, Carla F.M. Molthoff, et al.. (1999). An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma. BJOG An International Journal of Obstetrics & Gynaecology. 106(1). 31–37. 8 indexed citations
5.
Choy, Ernest, Dimitrios Kassimos, C T Ravirajan, et al.. (1999). The engineered human anti-tumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis.. PubMed. 26(11). 2310–7. 7 indexed citations
6.
Molthoff, Carla F.M., Peter Kenemans, Jan C. Roos, et al.. (1998). Biodistribution of 111 In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01. Cancer Immunology Immunotherapy. 47(1). 39–46. 16 indexed citations
7.
Heath, Patricia K., Mark Sopwith, J Freeman, et al.. (1997). Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. The Lancet. 349(9051). 521–524. 310 indexed citations
8.
Molthoff, Carla F.M., Alan C. Perkins, René H.M. Verheijen, et al.. (1996). Biodistribution of (111)indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose.. PubMed. 56(22). 5179–85. 19 indexed citations
9.
10.
Dhainaut, Jean-François, Jean‐Louis Vincent, Christian Richard, et al.. (1995). CDP571, a humanized antibody to human tumor necrosis factor-alpha. Critical Care Medicine. 23(9). 1461–1469. 96 indexed citations
11.
Stephens, Sue, Spencer Emtage, L Chaplin, et al.. (1995). Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses.. PubMed. 85(4). 668–74. 99 indexed citations
12.
Espiner, Eric A., Chris Frampton, Hamid Ikram, et al.. (1990). Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects.. Hypertension. 16(3). 269–276. 74 indexed citations
13.
Bouloux, Pierre‐Marc, David I. Perrett, Mark Sopwith, & G. M. Besser. (1986). An in-situ isolated rat adrenal perfusion system for study of neurally mediated catecholamine secretion: effects of morphine, a Met-enkephalin analogue, and naloxone on catecholamine secretion. Journal of Endocrinology. 111(1). 7–15. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alaa Afify Breakdown of academic impact, for papers by Nathalie Bâ Breakdown of academic impact, for papers by Noriyoshi Ogawa Breakdown of academic impact, for papers by J. Herbert Breakdown of academic impact, for papers by Isaac T. W. Harley Breakdown of academic impact, for papers by Makoto Sueishi Breakdown of academic impact, for papers by Toshihiko Hidaka Breakdown of academic impact, for papers by S Fukuhara Breakdown of academic impact, for papers by Nicholas K. Brown Breakdown of academic impact, for papers by Irena Kirman
Rankless by CCL
2026